These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23200166)

  • 1. [Severe pseudouveitis associated with moxifloxacin therapy].
    Duncombe A; Gueudry J; Massy N; Chapuzet C; Gueit I; Muraine M
    J Fr Ophtalmol; 2013 Feb; 36(2):146-50. PubMed ID: 23200166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin.
    Wefers Bettink-Remeijer M; Brouwers K; van Langenhove L; De Waard PW; Missotten TO; Martinez Ciriano JP; Van Aken E
    Eye (Lond); 2009 Dec; 23(12):2260-2. PubMed ID: 19851342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acute and bilateral uveitis secondary to moxifloxacin].
    Bringas Calvo R; Iglesias Cortiñas D
    Arch Soc Esp Oftalmol; 2004 Jul; 79(7):357-9. PubMed ID: 15286907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
    Prescrire Int; 2009 Oct; 18(103):206. PubMed ID: 19882787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral uveitis associated with fluoroquinolone therapy.
    Hinkle DM; Dacey MS; Mandelcorn E; Kalyani P; Mauro J; Bates JH; Soukasian SH; Holland GN; Foster CS; Fraunfelder FT; Davis JL; Fraunfelder FW
    Cutan Ocul Toxicol; 2012 Jun; 31(2):111-6. PubMed ID: 21981449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M; Anzueto A
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin--a new fluoroquinolone antibacterial.
    Drug Ther Bull; 2004 Aug; 42(8):61-2. PubMed ID: 15310155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with moxifloxacin in patients with respiratory tract infections.
    Faich GA; Morganroth J; Whitehouse AB; Brar JS; Arcuri P; Kowalsky SF; Haverstock DC; Celesk RA; Church DA
    Ann Pharmacother; 2004 May; 38(5):749-54. PubMed ID: 15026565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
    Simoens S; Decramer M
    Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilateral acute iris transillumination following systemic moxifloxacin for respiratory illness: report of two cases and review of the literature.
    Morshedi RG; Bettis DI; Moshirfar M; Vitale AT
    Ocul Immunol Inflamm; 2012 Aug; 20(4):266-72. PubMed ID: 22694259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced immune thrombocytopenia due to moxifloxacin.
    Coker TJ
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23329709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe sequelae in bilateral acute iris transillumination syndrome secondary to the use of oral moxifloxacin: a case report.
    Rivera-Valdivia N; Arteaga-Rivera K; Reyes-Guanes J; Neira-Segura N; de-la-Torre A
    J Med Case Rep; 2021 Sep; 15(1):462. PubMed ID: 34537056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin.
    Willermain F; Deflorenne C; Bouffioux C; Janssens X; Koch P; Caspers L
    Eye (Lond); 2010 Aug; 24(8):1419; author reply 1419-20. PubMed ID: 20379213
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug Points: tachycardia associated with moxifloxacin.
    Siepmann M; Kirch W
    BMJ; 2001 Jan; 322(7277):23. PubMed ID: 11141146
    [No Abstract]   [Full Text] [Related]  

  • 15. [Moxifloxacin and hepatic toxicity].
    Franco Hidalgo S; Prieto de Paula JM; García Lorenzo R; Salado Valdivieso I
    Gastroenterol Hepatol; 2009 Dec; 32(10):719-20. PubMed ID: 19664854
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy of moxifloxacin in the treatment of respiratory tract infections: the Croatian post-marketing study].
    Kuzman I; Kincl-Brodnjak V; Ermakora S; Kovacević D; Kuzman T
    Lijec Vjesn; 2005; 127(3-4):77-81. PubMed ID: 16193858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.
    Van Bambeke F; Tulkens PM
    Drug Saf; 2009; 32(5):359-78. PubMed ID: 19419232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
    Chou HW; Wang JL; Chang CH; Lee JJ; Shau WY; Lai MS
    Clin Infect Dis; 2013 Oct; 57(7):971-80. PubMed ID: 23948133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin as the likely cause of drug-induced linear immunoglobulin A bullous dermatosis.
    Kovacic D; Fox M; Reichenberg J
    J Drugs Dermatol; 2008 Aug; 7(8):794-5. PubMed ID: 18720700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.